Equillium is a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders. The Company's pipeline consists of novel immunomodulatory assets and a product platform targeting immuno-inflammatory pathways.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/11/25 | $50,000,000 | Venture Debt & Equity |
Adage Capital Partners ADAR1 Capital Management  Coastlands Capital Janus Henderson Investors Woodline Partners | undisclosed |
